Tag Archives: healthcare

Rhapsody and Corepoint merge to advance Interoperability in Healthcare

HG Capital

10 July 2019. Rhapsody, a global leader in healthcare data interoperability, today announced that the company will merge with Corepoint Health, the supplier of the Best in KLAS® healthcare integration platform. The transaction will bring together two companies at the forefront of interoperability and create a dynamic combination of technology, talent, services, and trusted customer relationships to address the most complex healthcare interoperability challenges.

Please find the full press release here

“We move decisively when perfect opportunities present themselves,” said Philippe Houssiau, Operating Partner at Hg. “The opportunity to bring Corepoint and Rhapsody together was incredibly compelling. Our investments in these two phenomenal companies demonstrate how excited we are about the future of interoperability. Rhapsody is off to an amazing start as an independent company: joining forces with Corepoint will enable the combined team to accelerate the delivery of FHIR-based services, cloud-based integration solutions and support for regional and national interoperability frameworks.”

Categories: News

Tags:

Rhapsody and Corepoint merge to advance Interoperability in Healthcare

No Comments

HG Capital

10 July 2019. Rhapsody, a global leader in healthcare data interoperability, today announced that the company will merge with Corepoint Health, the supplier of the Best in KLAS® healthcare integration platform. The transaction will bring together two companies at the forefront of interoperability and create a dynamic combination of technology, talent, services, and trusted customer relationships to address the most complex healthcare interoperability challenges.

Please find the full press release here

“We move decisively when perfect opportunities present themselves,” said Philippe Houssiau, Operating Partner at Hg. “The opportunity to bring Corepoint and Rhapsody together was incredibly compelling. Our investments in these two phenomenal companies demonstrate how excited we are about the future of interoperability. Rhapsody is off to an amazing start as an independent company: joining forces with Corepoint will enable the combined team to accelerate the delivery of FHIR-based services, cloud-based integration solutions and support for regional and national interoperability frameworks.”

Categories: News

Tags:

Ardian arranges unitranche financing for 21 Invest France’s acquisition of controlling stake in Landanger

Ardian

Paris, July 5th 2019 – Ardian, a world leading private investment house, today announces the arrangement of a unitranche financing facility to support 21 Invest France’s partnership with Landanger, the French leader in the manufacturing and distribution of reusable surgical instruments and maintenance services. The unitranche package will also include a committed acquisition facility to finance future build-ups.
Founded in 1947 in Chaumont, Landanger has become a leading player in France with an international presence in nearly 60 countries. Through the reputable Landanger and Delacroix-Chevalier brands, the family-run company has developed a strong expertise in the design and distribution of surgical instruments for open and minimally invasive surgeries, especially in cardiovascular and thoracic applications. It has also maintained its historic expertise in the manufacturing of complex ancillaries for orthopedic implants through its Maire-Didier brand.
Thanks to a wide range of innovative products (7,500 SKUs), a strong commitment to quality of service, and a well-established presence in France, the Landanger Group works with 85% of French public and private hospitals and clinics, with which it has formed deep and long-standing relationships.
With state-of-the-art technical expertise and a recognized quality of service, Landanger has a strong position in France but also internationally, with foreign sales representing roughly 30% of its turnover. This is driven by the rising number of surgical operations and the growing need for specialty instruments in increasingly complex procedures.
21 Invest France will help Landanger strengthen its leading position in France by expanding its offer through improved innovation capacity (recent launch of a new Ear, Nose and Throat range), and to accelerate its internationalization. Targeted build-ups, facilitated by the unitranche facility provided by Ardian, are intended to further support the growth plan, bringing synergies both in terms of products and geographic coverage.
Grégory Pernot, Director in the Private Debt team of Ardian highlighted: “As an agile and flexible financing product, the unitranche immediately resonated with Landanger and 21 Invest’s ambition for its strategic growth plan, both in France and internationally.”
Benoit Landanger, CEO, commented: “The Landanger Group has historically been driven by a dynamic innovation strategy, and I am happy to partner up with 21 Invest France and benefit from the support of Ardian’s financing in order to bring the company to its next expansion phase.”
François Barbier, Managing Partner & CEO and Antoine Vigneron, Partner at 21 Invest France, commented: “Landanger has showcased its technical know-how and long-standing expertise in surgical instruments since its inception over 70 years ago. We look forward to embarking on the next stage of growth alongside the CEO. We firmly believe Landanger will become an international leader in surgical instruments, supported by Ardian’s unitranche financing, which will grant us flexibility and speed of execution to strategically enhance the company’s footprint.”
Guillaume Chinardet, Head of Private Debt France and Managing Director at Ardian, concluded: “We have been very impressed by the company’s achievements in this space, and are delighted and proud to be a key partner of Landanger going forward. Landanger stands for the 119th transaction since the creation of Ardian’s Private Debt activity, reflecting the longstanding track-record of the team since 2005.”

ABOUT ARDIAN

Ardian is a world-leading private investment house with assets of US$90bn managed or advised in Europe, the Americas and Asia. The company is majority-owned by its employees. It keeps entrepreneurship at its heart and focuses on delivering excellent investment performance to its global investor base.
Through its commitment to shared outcomes for all stakeholders, Ardian’s activities fuel individual, corporate and economic growth around the world.
Holding close its core values of excellence, loyalty and entrepreneurship, Ardian maintains a truly global network, with more than 610 employees working from fifteen offices across Europe (Frankfurt, Jersey, London, Luxembourg, Madrid, Milan, Paris and Zurich), the Americas (New York, San Francisco and Santiago) and Asia (Beijing, Singapore, Tokyo and Seoul). It manages funds on behalf of around 880 clients through five pillars of investment expertise: Fund of Funds, Direct Funds, Infrastructure, Real Estate and Private Debt.
www.ardian.com

ABOUT 21 INVEST

21 Invest supports resilient mid-market companies based in France, Italy and Poland through local Funds and accompanies them in a new stage of development. 21 Invest positions itself as an active shareholder alongside management teams, providing a strategic vision for companies, enabling them to accelerate their growth, improve their operational efficiency and achieve ambitious long-term projects. Over the past 27 years, 21 Invest has completed more than 105 investments and raised more than € 2 billion from European and global institutional investors.
www.21invest.com

LIST OF PARTIES INVOLVED

Landanger: Benoit Landanger
21 Invest: François Barbier, Antoine Vigneron, Dorothée Chatain
Ardian Private Debt: Guillaume Chinardet, Grégory Pernot, Clément Chidiac
Financing Legal Advisor (Ardian): Willkie Farr & Gallagher – Paul Lombard, Igor Kukhta, Ghita Lorabi

Categories: News

Tags:

SIFI to acquire a pharmaceutical product portfolio in France

SIFI, the Italian leader in ophthalmology, has acquired Dacudoses and Novoptine, leading ophthalmic antiseptic brands in France with a total turnover of about € 6 million, from Laboratoire Gifrer Barbezat.

Dacudoses is the leading reimbursed brand of the French ophthalmic antiseptic segment, prescribed by ophthalmologists and general practitioners. Dacudoses is commonly used as an eyewash in case of light conjunctivitis and/or infections, benefitting from a very strong brand recognition in France.

Novoptine is an overt-the-counter antiseptic collyrium used to treat eye infections and conjunctivitis.

SIFI will market both products directly through its subsidiary SIFI France, starting from January 2020. The reference market segment is expected to grow thanks to increased incidence of eye disorders, such as bacterial and allergic conjunctivitis, among the aging population.

According to the Ocular Surface Infections Guidelines by AFSSAPS (Agence Française de Sécurité Sanitaire des Produits de Santé), non-serious bacterial conjunctivitis in adults, in the absence of risk factors, should be treated by washing the eye with saline solution associated with antiseptic solutions instead of using antibiotics.

With a leadership position in Italy, Romania and Turkey, a consolidated presence in Mexico and more recently also in Spain, SIFI is implementing an international expansion strategy, with the aim of becoming a key independent player in ophthalmology, leveraging on its know-how, expertise and unique assets.

After this acquisition, thanks to fast growing export, SIFI’s international sales will represent about 40% of turnover and are expected to increase significantly in the coming years.

“This strategic deal represents a significant milestone for our company, being the first acquisition made since our foundation, and will accelerate our penetration into France, one of the largest and most competitive markets in Western Europe.” declared Fabrizio Chines, Chairman and CEO of SIFI “Dacudoses and Novoptine are very complementary with our proprietary portfolio, which we expect to launch through SIFI France starting from 2020, in line with a well-balanced regulatory, market access and marketing strategy.“

“SIFI is an example of excellence in our portfolio that we are proud to support in its international expansion” commented Alessandro Benetton, Founding Managing Partner of 21 Invest “This operation is strategic to reach its ambitious goal of creating a leading company in the international ophthalmic market”.

Funding for the acquisition, along with other refinancing facilities, was provided by a consortium of Italian banks.

Categories: News

Tags:

Ampersand Completes Growth Equity Investment in N2 Biomedical

Bedford, MA – June 18, 2019 – N2 Biomedical, a leading provider of coating and surface treatment solutions to the medical device industry, announced today the majority recapitalization of the company by Ampersand Capital Partners. As part of the transaction N2 also announced the appointment of Randall Sword, an executive with 30 years of experience in the medical device sector, as President and CEO. Mr. Sword has served in executive leadership positions at multiple leading medical device manufacturing companies, including as CEO of AdvancedCath.

Since its founding in 2013, N2 has processed millions of medical devices utilized in orthopedic, cardiovascular, and other procedures. The company’s proprietary processes are utilized in a variety of critical settings to improve material characteristics including lubricity, infection resistance, biocompatibility and tissue integration, and wear and corrosion resistance.

Mr. Sword commented, “I am very pleased to join a company with such unique technologies and a history of developing innovative coating and surface modification solutions for the medical device industry. With the support of an experienced and successful medical device investor in Ampersand, we look forward to further enhancing the high level of service and innovation customers have come to expect from N2.”

Trevor Wahlbrink, a Partner at Ampersand added, “N2 is an excellent fit with Ampersand’s investment strategy in the medical device industry, in which we target industry leaders with differentiated manufacturing technologies that address the critical needs of patients and global medical device OEMs. We are very excited to partner with Randall and the rest of the N2 management team to continue the company’s growth trajectory and support the expansion of N2’s service offering in this rapidly evolving industry.”

N2 co-founders Mark Little and Eric Tobin remain shareholders in the company. Mr. Little will remain on the Board of Directors, and Mr. Tobin will remain in his current position as the company’s Chief Operating Officer.

About N2 Biomedical

Established in 2013, N2 provides coating and surface treatment development and application services for implantable and other medical devices utilized in orthopedic, cardiovascular, and other healthcare end-markets. N2 is ISO-13485 certified, FDA GMP-compliant, and operates in a 30,000 square foot facility with laboratory, manufacturing, and cleanroom space to service all customer and regulatory requirements. The company leverages its proprietary processes and equipment to provide customized solutions that enhance the characteristics of various materials in critical applications, including lubricity, infection resistance, biocompatibility and tissue integration, and wear and corrosion resistance. Additional information about N2 Biomedical is available at N2bio.com.

About Ampersand Capital Partners

Founded in 1988, Ampersand is a middle market private equity firm dedicated to growth-oriented investments in the healthcare sector. With offices in Boston, MA and Amsterdam, Netherlands, Ampersand leverages a unique blend of private equity and operating experience to build value and drive superior long-term performance alongside its portfolio company management teams. Ampersand has helped build numerous market-leading companies across each of its core healthcare sectors, including Avista Pharma Solutions, Brammer Bio, Confluent Medical, Genewiz, Genoptix, Talecris Biotherapeutics, and Viracor-IBT Laboratories. Additional information about Ampersand is available at ampersandcapital.com.

Categories: News

Tags:

Bure has acquired shares in Mentice AB

Bure

2019-06-18 13:00

Bure Equity AB (publ) (“Bure”) has, in connection with the IPO of Mentice AB (“Ovzon”), acquired 2,448,000 shares corresponding to 10.1 percent of the total number of shares and votes in the company for SEK 120 million. Mentice was listed today, 18 June 2019, on Nasdaq First North Premier Stockholm.

Bure Equity AB (publ)


For more information contact:

Henrik Blomquist, CEO
Tel. +46 (0)8-614 00 20

The information was submitted for publication at 13:00 CET on 18 June 2019.

 

 

Categories: News

Tags:

Nordic Capital builds on its existing Healthcare sector track record with further expansion into US market

Nordic Capital

and announces latest investment in US-based provider of life sciences software

The Advisor to the Nordic Capital Funds announces its further expansion into the US, building on Nordic Capital’s reputation as a leading investor in global healthcare and already established track record in the US market. After ten years of Nordic Capital successfully investing in the US healthcare space, the Advisor to the Nordic Capital Funds will open new offices in New York during the Autumn of 2019. The initiative is led by Dr Raj Shah M.D, Partner and Co-Head of Healthcare. Thomas Vetander, Partner and an experienced member of the Healthcare team will relocate from Stockholm to New York later this year.

Nordic Capital is one of the most active and experienced investors in healthcare globally and enjoys a long track-record of investing in US-based healthcare companies and building industry leaders. Since inception in 1989, Nordic Capital has invested over EUR 5.4 billion in healthcare companies, of which c. EUR 1.4 billion has been invested into US-based healthcare companies.

Dr Raj Shah M.D, Partner at the Advisor to the Nordic Capital Funds, said: “The US is a key global market for healthcare companies and offers opportunities that are consistent with Nordic Capital’s healthcare investment strategy for both new investments as well as existing portfolio companies. Nordic Capital has been investing in the US healthcare market for many years and establishing an advisory office in the US for healthcare is a natural evolution. We look forward to building on Nordic Capital’s thirty-year track record in global healthcare investment.”

Thomas Vetander, Partner at the Advisor to the Nordic Capital Funds, added: “Nordic Capital favours segments that are well placed to achieve long term growth driven by favourable sector trends such as changing population demographics, continued technological and scientific innovation, and public and private cost pressures. Nordic Capital looks to partner with businesses where it can bring a powerful combination of capital and strong operational skills to accelerate growth and support positive transformative change.”

Nordic Capital Fund IX’s latest investment is US-based ArisGlobal, a leading global provider of life sciences software that is transforming the way today’s most successful life sciences companies develop medical breakthroughs and bring new drugs to market. In January 2019 Nordic Capital Fund IX acquired Orchid Orthopedic Solutions, a world leader in design and manufacture of orthopaedic implants based in Holt, Michigan. Another US based portfolio company is ERT, a Nordic Capital Fund VIII investment, which is a Pennsylvania-based data and technology company offering solutions to minimise risk and uncertainty for its customers’ clinical trials.

To date, Nordic Capital has invested a total of EUR 14 billion, of which approx. 40% has been deployed in healthcare globally.

Footnote: “Nordic Capital” or the “Nordic Capital Funds” refers to any, or all, Nordic Capital branded or associated funds or investment vehicles and their respective management entities. Nordic Capital is advised by its exclusive advisors, the NC Advisory entities and the Nordic Capital Investment Advisory entities, any or all of which is referred to as the Advisor to the Nordic Capital Funds.

Media contacts:

Nordic Capital

Katarina Janerud, Communications Manager
Advisor to the Nordic Capital Funds
Tel: +46 8 440 50 50
e-mail: katarina.janerud@nordiccapital.com


About Nordic Capital

Nordic Capital is a leading private equity investor with a resolute commitment to creating stronger, sustainable businesses through operational improvement and transformative growth. Nordic Capital focuses on selected regions and sectors where it has deep experience and a proven track record. Core sectors are Healthcare, Technology & Payments, Financial Services and in addition, Industrial Goods & Services and Consumer. Key regions are the Nordics, Northern Europe and globally for Healthcare. Since inception in 1989, Nordic Capital has invested EUR 14 billion in over 100 investments. The most recent fund is Nordic Capital Fund IX with EUR 4.3 billion in committed capital, principally provided by international institutional investors such as pension funds. The Nordic Capital Funds and vehicles are based in Jersey. They are advised by several advisory entities, which are based in Sweden, Denmark, Finland, Norway, Germany, the UK and the US, any or all of which is referred to as the Advisor to the Nordic Capital Funds. For further information about Nordic Capital, please visit www.nordiccapital.com

Categories: News

Tags:

Nordic Capital acquires ArisGlobal, a leading global provider of life sciences software

Nordic Capital

  • As a leading healthcare and technology investor, Nordic Capital will further support and accelerate ArisGlobal’s growth

Nordic Capital Fund IX today announced an agreement to acquire US-headquartered ArisGlobal, a leading global provider of innovative SaaS software solutions, which are transforming the way the most successful life sciences companies handle drug safety, clinical development, regulatory compliance, and medical affairs. Drawing on its deep understanding of both the healthcare and technology sectors, Nordic Capital will support ArisGlobal’s continued development. The founders of ArisGlobal will remain as minority shareholders.   

ArisGlobal is a visionary technology company that has successfully developed a next-generation platform that uses advanced cognitive computing and machine learning to automate all core functions of drug safety, regulatory compliance and medical affairs. Currently, more than 200 life sciences companies such as AstraZeneca, NovoNordisk, Merck and Novartis, CROs and government health authorities, as well as 40 of the top 50 global biopharmaceutical companies, rely on ArisGlobal’s solutions. Benefiting from deep expertise, longstanding customer relationships and a 30-year track record, ArisGlobal assists clients in maintaining regulatory compliance, managing and mitigating risk, and improving operational efficiency.

ArisGlobal is headquartered in Miami, FL, USA, with regional offices in Europe, India, Japan and China. It has 1,200 employees globally and c. USD 100 million of annual revenues. In recent years, ArisGlobal has invested in transforming its traditional on-premise offering to a hosted solution sold through a SaaS model.

“This transaction is representative of our rapid growth in the global life sciences industry, which is further proven by the adoption of our LifeSphere platform by the U.S. FDA. We look forward to partnering with Nordic Capital to leverage our common vision, values and combined talents to offer the most innovative technology platform to the life science industry. Nordic Capital has extensive experience in the pharma IT market from previous investments, and a proven track-record building strong teams which can further accelerate ArisGlobal’s growth. Nordic Capital also has a long track-record of partnerships with founding families and is well positioned to support our continued growth over the years to come,” says Deepak Abbhi, Founder and Chairman of the Board of ArisGlobal.

“We are now embarking on a new chapter that will accelerate our ability to achieve our mission. Our unwavering focus on our customers’ needs will continue to be the core of who we are as a company. It drives the development of our LifeSphere platform. It fuels our passion for becoming the premier innovative technology company in the world. We share a closely aligned vision with Nordic Capital for the future of the industry and this partnership gives us immediate access to deep resources and expert guidance that will help us in our journey. I am more excited than ever about the future,” says Sankesh Abbhi, President and CEO of ArisGlobal.

“This investment lies at the heart of Nordic Capital’s investment strategy as a leading healthcare and technology investor. We have followed the pharmacovigilance market closely for several years and know the industry well. ArisGlobal has a top-quality management team and its success is based on its commitment to develop leading and innovative cloud-based software that help organisations maintain regulatory compliance, manage and mitigate risk, and improve operational efficiency. ArisGlobal’s SaaS native software is becoming the preferred choice for life sciences companies because it enables them to quickly implement cost-effective solutions for drug safety reporting, regulatory compliance, and medical affairs,” says Daniel Berglund, Principal at the Advisor to the Nordic Capital Funds.

“The US is a key global market for healthcare companies and offers opportunities that are consistent with Nordic Capital’s investment strategy. ArisGlobal is a company that fits well within the portfolio and is well placed to achieve long term growth driven by favourable sector trends such as continued technological and scientific innovation, serving an attractive innovation driven customer base. We look forward to partnering with ArisGlobal where Nordic Capital can deploy its unique combination of capital and strong operational skills to accelerate growth and support positive transformative change.” says Dr Raj Shah, Partner, Co-Head of Healthcare at the Advisor to the Nordic Capital Funds.

The parties have agreed to not disclose any financial details. The transaction is subject to customary regulatory approvals.

Since inception in 1989, Nordic Capital has made 28 healthcare platform investments across Europe and North America and an additional 14 investments in the Technology & Payments sector, supporting active value creation agendas to build industry winners. Previous investments in the US include ERT, a leading provider of high-quality patient safety and efficacy endpoint data collection solutions for use in clinical drug development, and Orchid Orthopedics Solutions, a leader in the design and manufacture of implants to the global orthopaedic market.

The investment in ArisGlobal coincides with the Advisor to the Nordic Capital Funds expanding into the US, where it will open a permanent office in New York during the Autumnof 2019, building on Nordic Capital’s reputation as a leading investor in global healthcare and already established track record in the US market.

Footnote: “Nordic Capital” or “Nordic Capital Funds” refers to any, or all, Nordic Capital branded or associated funds or investments vehicles and their associated management entities. Nordic Capital is advised by its exclusive advisors, the NC Advisory entities and the Nordic Capital Investment Advisory entities, any or all of which is referred to as the Advisor to the Nordic Capital Funds.

 

Press contacts:

Nordic Capital
Katarina Janerud, Communications Manager,
The Advisor to the Nordic Capital Funds
Tel: +46 8 440 50 50
e-mail: katarina.janerud@nordiccapital.com

 

ArisGlobal

Sam Stein, VP, Marketing & Commercial Strategy
Tel: +1-786-814-0365
e-mail: sstein@arisglobal.com


About ArisGlobal

ArisGlobal is a visionary technology company that’s transforming the way today’s most successful life sciences companies develop breakthroughs and bring new products to market. ArisGlobal’s LifeSphere® drug development platform integrates cognitive computing technologies to automate the core functions of the product lifecycle. Designed with deep expertise and a long-term perspective that spans more than 30 years, the LifeSphere platform delivers actionable insights, boosts efficiency, ensures compliance, and lowers total cost of ownership through a multi-tenant SaaS model. ArisGlobal is headquartered in Miami, Florida, USA, with regional offices in Europe, India, Japan and China.  For more information about ArisGlobal, please visit www.arisglobal.com

 

About Nordic Capital

Nordic Capital is a leading private equity investor with a resolute commitment to creating stronger, sustainable businesses through operational improvement and transformative growth. Nordic Capital focuses on selected regions and sectors where it has deep experience and a proven track record. Core sectors are Healthcare, Technology & Payments, Financial Services and in addition, Industrial Goods & Services and Consumer. Key regions are the Nordics, Northern Europe and globally for Healthcare. Since inception in 1989, Nordic Capital has invested EUR 14 billion in over 100 investments. The most recent fund is Nordic Capital Fund IX with EUR 4.3 billion in committed capital, principally provided by international institutional investors such as pension funds. The Nordic Capital Funds and vehicles are based in Jersey. They are advised by several advisory entities, which are based in Sweden, Denmark, Finland, Norway, Germany, the UK and the US, any or all of which are referred to as the Advisor to the Nordic Capital Funds. For further information about Nordic Capital, please visit www.nordiccapital.com

Categories: News

Tags:

EQT to sell Press Ganey

eqt

  • EQT VII to sell Press Ganey, a leading provider of safety, quality, patient experience and workforce engagement solutions for healthcare organizations in the US, to a consortium of funds managed by affiliates of Ares Management Corporation, Leonard Green & Partners, and other co-investors
  • During EQT’s ownership, Press Ganey has enhanced its position as the key thought leader and partner to US healthcare organizations in helping them transform care and achieve improved financial, operational and clinical performance
  • The sale of Press Ganey marks the first portfolio company exit by EQT’s US Private Equity strategy

The EQT VII fund (“EQT” or “EQT VII”) has entered into an agreement to sell Press Ganey (“the Company”) to a consortium of funds managed by Leonard Green & Partners, L.P. (“LGP”), affiliates of Ares Management Corporation (NYSE: ARES), and other co-investors.

Press Ganey is a leading provider of safety, quality, patient experience and workforce engagement solutions for healthcare organizations in the US. The Company serves over 41,000 healthcare facilities, more than 75% of US acute care hospitals and over 2,500 outpatient facilities. EQT VII acquired Press Ganey in a public-to-private transaction in 2016, marking EQT VII’s first direct investment in North America.

Together with the management team, EQT has supported Press Ganey in its journey to transform healthcare through measurement, integrated analytics, and advisory services. During EQT’s ownership, Press Ganey grew revenue organically and completed multiple strategic acquisitions, strengthening Press Ganey’s position in the US healthcare market. With EQT’s support, Press Ganey introduced its integrated suite of transformational solutions and developed PGO 2.0, the Company’s next generation digital platform, enabling cross domain analytics across the continuum of care.

Pat Ryan, Executive Chairman of Press Ganey, said: “The team at Press Ganey has been fortunate to have a fantastic partnership with EQT, and they have played a critical role in our success. We will always be appreciative of their vision, insight and friendship. We look forward to working with our new partners at Ares and LGP as we continue on our successful growth journey and further our mission to reduce patient suffering.”

Eric Liu, Partner at EQT Partners and Investment Advisor to EQT VII, said: “Press Ganey plays an integral role in the US healthcare system and we have been proud to support its mission of delivering safe, high quality care for patients, and supporting the caregivers that serve them. It has been a pleasure to partner with the management team, which has done a fantastic job in continuing to advance thought leadership and product innovation across the industry.”

The transaction is subject to customary approvals and is expected to close in the third quarter of 2019.

Barclays and Goldman Sachs acted as joint financial advisors and Simpson Thacher & Bartlett acted as legal advisor to EQT and Press Ganey.

Contact
Eric Liu, Partner at EQT Partners, Investment Advisor to EQT VII, +1 917 281 0850
US inquiries: Stephanie Greengarten, +1 646 687 6810, stephanie.greengarten@eqtpartners.com
International inquiries: EQT Press Office, +46 8 506 55 334, press@eqtpartners.com

About EQT
EQT is a leading investment firm with more than EUR 61 billion in raised capital across 29 funds and around EUR 40 billion in assets under management. EQT funds have portfolio companies in Europe, Asia and the US with total sales of more than EUR 21 billion and approximately 127,000 employees. EQT works with portfolio companies to achieve sustainable growth, operational excellence and market leadership.

More info: www.eqtpartners.com

About Press Ganey
Recognized as a leader in performance improvement for nearly 30 years, Press Ganey partners with more than 41,000 healthcare facilities worldwide to create and sustain high-performing organizations, and, ultimately, improve the overall healthcare experience. The company offers a comprehensive portfolio of solutions to help clients operate efficiently, improve quality, increase market share and optimize reimbursement. Press Ganey works with clients from across the continuum of care – hospitals, medical practices, home care agencies and other providers.

More info: www.pressganey.com

 

Categories: News

Tags:

NEOMED-LABS / Pacific Biomarkers Strengthens its Immunology Franchise by Acquiring PAIRimmune

LAVAL, QC, June 6, 2019 – The recently merged NEOMED-LABS / Pacific Biomarkers (NLPBI), a leading immunology centric service provider specialized in assay development and clinical laboratory testing for vaccines and soluble large molecules, announced today the acquisition of PAIRimmune, a non-GLP preclinical immunology service provider based in Laval, Quebec.

With over 20 years of legacy in assay development, immunogenicity and efficacy predictive in vitro and in vivo models, PAIRimmune’s CEO Danielle Poirier and her team have a solid reputation for outstanding science within the community. Since 2015, they have been a CRO partner to small Biotech, academic groups and the most prestigious vaccine and large molecule Pharma companies.

“As a science-driven organization, nothing makes us happier than seeing talented scientists joining forces with us. This acquisition strengthens our ligand binding and neutralization assays R&D capabilities, and this is a determinant growth engine for each of our biomarkers, bioanalytical and vaccine divisions. PAIRimmune also increases our capacity and capabilities in flow cytometry and places us in a situation to answer positively to requests with either an in vivo, ex-vivo or immunohistology component. A perfect match!” said Dr Benoit Bouche, NLPBI President and Chief Executive Officer.

This acquisition reinforces NLPBI’s ability to serve the needs of the health industry from the preclinical stage where it is critical to develop robust data needed to make informed go/no-go decisions.

“The exponential growth of NLPBI these last years is impressive and proves the need for the emergence of a world class immunology specialist CRO. We are thrilled to become part of this story. Many of our employees are former GSK colleagues and old friends. Working in the same building in Laval gives us the feeling that we are already part of the family. Our clients will get access from day one to state-of-the-art labs and synergistic expertise that will result in an improved quality of service.”, said Danielle Poirier, President of PAIRimmune.

PAIRimmune will pursue its operations under the leadership of Danielle Poirier, Director of Preclinical Services and Matthieu Daugan, Associate Director of Preclinical Services.

PAIRimmune will be rebranded this fall at the same time as NEOMED-LABS and Pacific Biomarkers under a new corporate identity currently in development.

ABOUT NEOMED-LABS / Pacific Biomarkers

NEOMED-LABS / Pacific Biomarkers is a leading assay development and specialty clinical laboratory CRO whose versatile team of scientists and technology platforms were instrumental in the development, qualification, validation, and large-scale sample testing of assays that supported the FDA filing of almost 100 new molecular entities, including blockbuster vaccines and soluble large molecules. We proudly provide superior services and unrivaled expertise in immunology based on a client-centric team approach and expedited development time.

For more information, please visit: www.neomedlabs.com / www.pacbio.com

ABOUT PAIRimmune

PAIRimmune is a Contract Research Organization specialized in immunology evaluation for vaccine and immunotherapy development. We offer to our clients scientific methods combined with biopharma expertise to move forward early biological products. Based on in vivo and in vitro expertise, we build for our industry, academic and small biotech clients an adapted solution for their projects.

For more information, please visit: www.pairimmune.com

For more information, please contact:
Mounia Azzi
(514) 909-7714
mazzi@neomedlabs.com

Categories: News

Tags: